Physician profile
Eric R Thomas
NPI 1588636484
$7,115.99
in general payments reported to CMS, 2019-2025
21 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $753 · 2021: $1,720 · 2022: $2,501 · 2023: $405 · 2024: $401 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $5,202.05 | 2019-2022 | |
| Alimera Sciences, INC. | $852.97 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $285.49 | 2022-2025 | Lumigan |
| Apellis Pharmaceuticals, INC. | $158.59 | 2022-2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $100.23 | 2022-2025 | Eylea Hd |
| Alcon Vision LLC | $84.78 | 2023-2025 | Clareon, Tryptyr, Rocklatan |
| Dutch Ophthalmic, USA | $83.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $55.99 | 2025 | Iluvien |
| Genentech USA, INC. | $55.37 | 2021-2024 | Vabysmo, Lucentis |
| Bausch & Lomb Americas INC. | $30.26 | 2023-2024 | Xiidra, Xipere |
| Allergan, INC. | $26.41 | 2021 | |
| Rxsight INC | $24.72 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.30 | 2024 | Xdemvy |
| Astellas Pharma US INC | $19.56 | 2023 | |
| The Cameron-Ehlen Group, INC. | $18.43 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $18.37 | 2023 | |
| Eyepoint US, INC. | $17.97 | 2023 | |
| Biogen, INC. | $17.48 | 2022 | |
| Spark Therapeutics, INC. | $16.50 | 2019 | |
| Sandoz INC. | $13.55 | 2024 | Cimerli |
| Novartis Pharmaceuticals Corporation | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$197,862.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.